Neuroendocrine and Carcinoid Tumors
Neuroendocrine and carcinoid tumors are rare forms of cancer that develop in various parts of the body. Because these cancers are so rare, there are very few treatment centers in the United States with specialists who have sufficient experience with neuroendocrine tumors (NETs). Mount Sinai is one of them.
Our team has world-renowned experts who have been treating this rare disease for decades. If you or a loved one has NETs or a type of NETs, known as a carcinoid tumor, we encourage you to come to Mount Sinai. You will be joining our patients who come from across the country and around the world to meet with our specialists.
Your treatment plan will benefit from our interdisciplinary approach. We bring together experts in surgery, nuclear medicine, cardiology, pulmonology, cancer (oncology), blood (hematology), radiology, pathology, gastroenterology, endocrinology, and nutrition. Our unique knowledge enables us to diagnose and treat your NET disorder for a superior outcome.
We are extremely pleased to have Edward M. Wolin, MD, an internationally renowned authority on neuroendocrine tumors as our director. Dr. Wolin is a Professor of Medicine, Hematology, and Medical Oncology at the Icahn School of Medicine at Mount Sinai. He ensures that we have a robust research program and clinical trials. We are working to find the most effective treatments, including immunotherapy, biologic agents, targeted radiation therapy, and new approaches in molecular imaging for diagnosis.
Dr. Wolin serves as Co-Medical Director for the Carcinoid Cancer Foundation. He also serves on the Carcinoid Cancer Research Grants Scientific Review Committee for the American Association for Cancer Research. Dr. Wolin is a reviewer for numerous journals, including Journal of Clinical Oncology, Molecular Cancer Therapeutics, Clinical Cancer Research, and The Lancet Oncology.
For more information about Dr. Wolin and his work on NET, please view this video.